Search - tctmd.com

Displaying 441 - 460 of 1203

Sort: Relevancy | Date

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

Caitlin E. Cox

February 15, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

Presentation ISET 2017

Failure of Stent Therapy

Presenter: Gary M. Ansel

February 04, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Industry News

Medtronic Receives IDE Approval to Initiate Study of IN.PACT® Admiral® Drug-Coated Balloon for a New Indication in Patients with End-Stage Renal Disease

January 30, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

How to Treat BRS Restenosis (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Presenter: Fernando Alfonso, Juan F. Granada, Bruno Scheller

November 01, 2016

Presentation TCT 2016

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Presenter: Germano Di Sciascio, Bruno Scheller

November 01, 2016

Advertisement

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

Failure of Stent Therapy

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Medtronic Receives IDE Approval to Initiate Study of IN.PACT® Admiral® Drug-Coated Balloon for a New Indication in Patients with End-Stage Renal Disease

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

How to Treat BRS Restenosis (With Case Examples)

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content